Document:

Amendment to Custodian Agreement between the Trustee and JPMorgan

 Exhibit 10.1 

August 4, 2010 
  

			
	 The Bank of New York Mellon

101 Barclay Street, 22-W
 New York, NY
10286
 Attn: ADR Administration
	  	 BlackRock Asset Management International Inc.

400 Howard Street
 San Francisco, CA
94105
 Attn: Product Management Team - Intermediary

Investors and Exchange-Traded Products

Department

  

	 	Re:	 iShares®
COMEX® Gold Trust 

	 	    	Amendment No.1 to Custody Agreement dated as of July 1, 2010 

Ladies and Gentlemen: 

Reference is hereby made to the Custodian Agreement (the “Agreement”) dated as of July 1, 2010 between The Bank
of New York Mellon, a New York banking corporation, in its capacity as the trustee of the iShares®
COMEX® Gold Trust (the “Trust”) and JPMorgan Chase, N.A., a national banking association acting
through its London branch, pursuant to which the latter was appointed as custodian for the Trust (in such capacity, the “Custodian”). Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in
the Agreement. 
 This letter will evidence our agreement, with effect from the date hereof, that the provisions of the Agreement and the
Procedures notwithstanding, the Custodian will, at all times during the Covered Period, ensure that not more than 110 ounces of the Gold held by the Custodian under the Agreement may be held in the Unallocated Account and the entire remaining
balance will be held in the Allocated Account. 
 Except as modified hereby, the Agreement shall continue in full force and effect. 

This letter shall be governed by and construed pursuant to English law. 

Kindly indicate your agreement with the foregoing by countersigning a copy of this letter in the space provided below. 

Sincerely, 
 JPMorgan Chase Bank, N.A., London
branch 
  

			
	By:	 	 /s/ Andrew Lovell

	Name:	 	Andrew Lovell
	Title:	 	Vice President

 Consented and agreed to, 

 

									
	 The Bank of New York Mellon, in its capacity as

the Trustee of the
iShares®
COMEX® Gold Trust,
	  		  	 BlackRock Asset Management International Inc.,

in its capacity as sponsor,

					
	By:	  	 /s/ Josef F. Keenan
	  		  	By:	  	 /s/ Darek Wojnar

	Name:	  	Josef F. Keenan	  		  	Name:	  	Darek Wojnar
	Title:	  	Managing Director	  		  	Title:	  	Managing Director
					
		  		  		  	By:	  	 /s/ Jack Gee

		  		  		  	Name:	  	Jack Gee
		  		  		  	Title:	  	Managing Director2010 Management Incentive Plan

 EXHIBIT 10.7 

July 
1st - December
31st 2010 Management Incentive Plan 

The
July 1st - December
31st 2010 Management Incentive Plan (the “Plan”)
rewards selected employees of the Company, as defined below, for achievement of Objectives as defined in this plan. The plan is designed to support the growth and profitability of the organization. 

Definitions 
  

			
	 The Plan:
	 	The
July 1st -
December 31st 2010 Management Incentive
Plan.
		
	 The Company:
	 	Refers to Accelrys Inc., Symyx Technologies, Inc. and its affiliates.
		
	 Plan Participant:
	 	A regular employee of the Company in the following levels: CEO, Vice President, Director and eligible members of the Marketing organization; who are notified by the Company in
writing that they are participants in the Plan and are not already participating in an alternative commission or incentive plan and, in all such cases, are employed by the Company through December 31, 2010.
		
	 Non-GAAP Revenue:
	 	The Company’s aggregate revenue for the two quarters commencing July 1, 2010 and ending December 31, 2010, inclusive of revenue not recognized under GAAP as a result of the
merger with Symyx Technologies, Inc.
		
	 Non-GAAP Operating Income:
	 	Earnings before Interest and Taxes, excluding certain GAAP items as detailed by the Company in its filings

Term 
 This plan is effective for
the period ending December 31, 2010. 
 Plan Structure 

Each Plan Participant is eligible to earn a target incentive equal to his/her applicable percentage of base salary as notified by the Company. 

Earnings under the Plan result from successful performance against a combination of two Financial Metrics (Non GAAP revenue and non-GAAP Operating Income
Targets) and against Individual Performance Objectives. 
 Achievement under the plan is determined as follows: 

Vice President-level Participants and above: funding achievement under the Plan is tied to achievement against the two financial
matrices, weighted as follows: Non GAAP Revenue component accounts for 30% of the eligible amount; Non GAAP Operating Income accounts for 50% of the eligible amount; and if both such financial matrices are achieved, the individual may also earn up
to 20%, of the eligible amount subject to individual performance objectives, which may be awarded at the sole discretion of Accelrys’ CEO. 

Director-level Plan Participants: funding achievement under the Plan is tied to achievement against the two financial matrices,
weighted as follows: Non GAAP Revenue component accounts for 18.75% of the eligible amount; Non GAAP Operating Income accounts for 31.25% of the eligible amount; and if both such financial matrices are achieved, the individual may also earn up to
50%, of the eligible amount subject to individual performance objectives, which may be awarded at the sole discretion of Accelrys’ CEO. 

 Marketing Organization Plan Participants: funding achievement under the Plan is tied
to achievement against the two financial matrices, weighted as follows: Non GAAP Revenue component accounts for 18.75% of the eligible amount; Non GAAP Operating Income accounts for 31.25% of the eligible amount; and if both such financial matrices
are achieved, the individual may also earn up to 50%, of the eligible amount subject to individual performance objectives, which may be awarded at the sole discretion of Accelrys’ CEO. 

Payment Schedule 
 Incentives
shall be paid in the quarter that follows the completion of the Plan. 
 Payments under this plan are contingent upon signature on the
Acknowledgement (provided at the end of this plan) signifying acceptance of the plan terms. To be eligible for an award pursuant to this plan, a Plan Participant must remain employed continuously in good standing with the Company through
December 31, 2010. In addition, a Plan Participant who becomes eligible for participation following the effective date of the Plan and remains employed continuously in good standing with the Company during 2010 will receive payment against
achievement under the plan on a pro-rata basis. 
 General Provisions 

A Plan Participant shall not assign nor give any part of an incentive to any agent, customer or representative of the customer, or any other person, as an
inducement in obtaining an order. Unless expressly approved in advance by the CEO of the Company, a Plan Participant shall not accept any compensation from third parties related to sales of third party products or services made by the Company.

 In the event that any Plan Participant compensated in accordance with this plan owes any sum of money to the Company, including without
limitation draw payments, charge backs, and travel advances, the Company shall have the right at any time to offset such obligations against the employee’s base salary, commissions, or bonuses. 

The Company reserves the right without advance notice to: 
  

	 	1.	Accept, reject, or cancel any order; 

  

	 	2.	Make any adjustments or revisions to incentive rates, quotas, salaries, or any other matters pertaining to this Plan; and 

 

	 	3.	Resolve, in its sole and absolute discretion, any matters of interpretation under the Plan and matters not covered by the provisions of the Plan.

  

	 	4.	Modify or terminate this Plan at any time. 

 The
contents of this Plan are Company Proprietary and Confidential, and are not to be disclosed by any Plan Participant to any person who is not an employee of the Company. Any legal action brought concerning this Plan shall be brought only in the state
or federal courts of the country in which the Plan Participant is employed and both parties submit to venue and jurisdiction in these courts. This Plan contains the entire agreement of the parties with respect to the matters addressed herein, and
supersedes all other representations, statements and understandings concerning this subject matter. 
  

 
 Acknowledgement 

I hereby acknowledge that I have received, read, and accepted the July
1st – December
31st Management Incentive Plan and agree to be bound by
its terms. 
  

					
	Signature:	 		 	
	  
	 		 	  

		 		 	 DATEAmendment between Angiotech Pharmaceuticals, Inc. and Cook Incorporated

 EXHIBIT 10.1 

THE SYMBOL ‘***’ IS USED THROUGHOUT THIS EXHIBIT TO INDICATE THAT A PORTION 

OF THE EXHIBIT HAS BEEN OMITTED AS CONFIDENTIAL. 

MAY 20, 2010 AMENDMENT BETWEEN 

ANGIOTECH PHARMACEUTICALS, INC. AND 

COOK INCORPORATED MODIFYING JULY 9, 1997 

LICENSE AGREEMENT AMONG ANGIOTECH 

PHARMACEUTICALS, INC., BOSTON SCIENTIFIC 

CORPORATION, AND COOK INCORPORATED 

This Amendment is made and entered into as of this
20th day of May, 2010, by and between Angiotech
Pharmaceuticals, Inc., a corporation organized under the laws of the Province of British Columbia (“Angiotech”) and Cook Incorporated, an Indiana corporation (“Cook”). 

WHEREAS Angiotech, Cook and Boston Scientific Corporation (“BSC”) entered into the “License Agreement
Among Angiotech Pharmaceuticals, Inc., Boston Scientific Corporation and Cook Incorporated” dated July 9, 1997, under which Angiotech agreed to license on a co-exclusive basis to Cook and BSC certain patent rights, license rights, and
technology relating to the use of paclitaxel or certain other agents as a coating for certain medical devices, and Cook and Angiotech have amended that agreement on September 8, 2001, June 12, 2002 and September 24, 2004
(collectively, the “Angiotech License Agreement”); 
 WHEREAS Angiotech and Cook desire to amend the
Angiotech License Agreement as it relates to Angiotech and Cook as provided herein; 
 NOW THEREFORE, Angiotech
and Cook hereby agree as follows: 
 1. As between Angiotech and Cook, Section 4.2(a) of the Angiotech License Agreement is
replaced in its entirety with the following: 
 4.2(a) Royalties on Eligible Peripheral Vascular
Products. “Eligible Peripheral Vascular Products” means any Licensed Application in the Peripheral Vascular Field of Use. Within sixty (60) days after the end of each Contract Quarter during the term of the Cook License, Cook
shall pay Angiotech the following royalty (the “Cook Peripheral Vascular Royalty”) on Net Sales during that Contract Quarter of Eligible Peripheral Vascular Products, for sales by Cook and/or its Affiliates during such Contract Quarter,
calculated as follows: 
 (i) with respect to sales in a country of the European Union Geographical Area of
units of Eligible Peripheral Vascular Products that are Stent Products, the Cook Peripheral Vascular Royalty shall be [***] percent ([***]%) of the Net Sales of such units of Eligible Peripheral Vascular Products; 

(ii) with respect to sales in a country of the European Union Geographical Area of units of Eligible Peripheral Vascular
Products, other than Stent Products, covered in the country of sale by one or more valid and enforceable claims of a patent included in the Patent Rights, the Cook Peripheral Vascular Royalty shall be [***] percent ([***]%) of the Net Sales of such
units of Eligible Peripheral Vascular Products; 
  

 Page 1 of 2 

 (iii) with respect to sales in a country other than a country of the
European Union Geographical Area of units of Eligible Peripheral Vascular Products covered in the country of sale by one or more valid and enforceable claims of a patent included in the Patent Rights, the Cook Peripheral Vascular Royalty shall be
[***] percent ([***]%) of the Net Sales of such units of Eligible Peripheral Vascular Products; 
 (iv) as a
result of this Amendment, Cook need not calculate the Peripheral Vascular Base Unit Number as it no longer applies to the calculation of the Cook Peripheral Vascular Royalty; and 

(v) with respect to sales of the ZILVER
PTXTM product, the provisions of sections 4.2(a)(i-iv) and 4.3(b), as amended by this Amendment, shall apply
from the date of the first commercial sale of this product in any country in the world. 
 2. As between Angiotech and Cook,
Section [***] of the Angiotech License Agreement is amended by deleting the phrase: “[***]”. 
 3. Capitalized
terms not otherwise defined in this Amendment will carry their meaning as set forth in the Angiotech License Agreement. 
 4.
Cook and Angiotech expressly acknowledge that this Amendment shall not in any way bind BSC, and similarly, that Cook shall not in any way be bound by any amendment to the Angiotech License entered into exclusively between Angiotech and BSC.

 IN WITNESS WHEREOF, the undersigned have duly executed this Amendment as of the date set forth above.

  

			
	 ANGIOTECH PHARMACEUTICALS, INC.
	  	 COOK INCORPORATED

		
	 By: /s/ William L. Hunter
	  	 By: /s/ Rob Lyles

		
	 Name: William L. Hunter
	  	 By: Rob Lyles

		
	 Title: President & CEO
	  	 Title: VP, Global Business Unit Leader

THE SYMBOL ‘***’ IS USED THROUGHOUT THIS EXHIBIT TO INDICATE THAT A PORTION 

OF THE EXHIBIT HAS BEEN OMITTED AS CONFIDENTIAL. 
  

 Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]